Best response to ClaPD (IMWG criteria)
| . | Overall, N = 117 . | Lenalidomide refractory, N = 101 . | Bortezomib refractory, N = 94 . | Double refractory, N = 81 . |
|---|---|---|---|---|
| ORR (≥PR) | 70 (60) | 59 (58) | 52 (55) | 44 (54) |
| CBR (≥MR) | 78 (67) | 66 (65) | 59 (63) | 51 (63) |
| sCR | 6 (5) | 6 (6) | 5 (5) | 5 (6) |
| CR | 1 (1) | 1 (1) | 1 (1) | 1 (1) |
| VGPR | 20 (17) | 15 (15) | 14 (15) | 9 (11) |
| PR | 43 (37) | 37 (37) | 32 (34) | 29 (36) |
| MR | 8 (7) | 7 (7) | 7 (7) | 7 (9) |
| SD | 29 (25) | 23 (23) | 24 (26) | 20 (25) |
| PD | 10 (9) | 10 (10) | 8 (9) | 8 (10) |
| . | Overall, N = 117 . | Lenalidomide refractory, N = 101 . | Bortezomib refractory, N = 94 . | Double refractory, N = 81 . |
|---|---|---|---|---|
| ORR (≥PR) | 70 (60) | 59 (58) | 52 (55) | 44 (54) |
| CBR (≥MR) | 78 (67) | 66 (65) | 59 (63) | 51 (63) |
| sCR | 6 (5) | 6 (6) | 5 (5) | 5 (6) |
| CR | 1 (1) | 1 (1) | 1 (1) | 1 (1) |
| VGPR | 20 (17) | 15 (15) | 14 (15) | 9 (11) |
| PR | 43 (37) | 37 (37) | 32 (34) | 29 (36) |
| MR | 8 (7) | 7 (7) | 7 (7) | 7 (9) |
| SD | 29 (25) | 23 (23) | 24 (26) | 20 (25) |
| PD | 10 (9) | 10 (10) | 8 (9) | 8 (10) |
All values are n (%).
CBR, clinical benefit rate.